Post-treatment Long-term Follow-up Study of ADVM-043 Gene Therapy in Alpha-1 Antitrypsin Deficiency
Latest Information Update: 30 Sep 2024
At a glance
- Drugs ADVM 043 (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions
- Sponsors Adverum Biotechnologies
- 16 Mar 2022 Status changed from recruiting to completed.
- 22 Jan 2019 New trial record